drugset / Trial / NCT00833027

ALPHA Sitagliptin Add on to Metformin (0431-103)

NCT00833027

Phase 4 Completed 608 enrolled Merck Sharp & Dohme LLC
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin

Timeline

Start
2008-03-01
Primary completion
2009-10-30
Completion
2009-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Sitagliptin Small molecule 100 mg